A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21025R6" target="_blank" >RIV/61988987:17110/20:A21025R6 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00843989:_____/20:E0108452
Výsledek na webu
<a href="https://www.mdpi.com/2072-6694/12/5/1333" target="_blank" >https://www.mdpi.com/2072-6694/12/5/1333</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cancers12051333" target="_blank" >10.3390/cancers12051333</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers
Popis výsledku v původním jazyce
Hematological malignancies comprise over a hundred different types of cancers and account for around 6.5% of all cancers. Despite the significant improvements in diagnosis and treatment, many of those cancers remain incurable. In recent years, cancer cell-based therapy has become a promising approach to treat those incurable hematological malignancies with striking results in different clinical trials. The most investigated, and the one that has advanced the most, is the cell-based therapy with T lymphocytes modified with chimeric antigen receptors. Those promising initial results prepared the ground to explore other cell-based therapies to treat patients with blood cancer. In this review, we want to provide an overview of the different types of cell-based therapies in blood cancer, describing them according to the cell source.
Název v anglickém jazyce
A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers
Popis výsledku anglicky
Hematological malignancies comprise over a hundred different types of cancers and account for around 6.5% of all cancers. Despite the significant improvements in diagnosis and treatment, many of those cancers remain incurable. In recent years, cancer cell-based therapy has become a promising approach to treat those incurable hematological malignancies with striking results in different clinical trials. The most investigated, and the one that has advanced the most, is the cell-based therapy with T lymphocytes modified with chimeric antigen receptors. Those promising initial results prepared the ground to explore other cell-based therapies to treat patients with blood cancer. In this review, we want to provide an overview of the different types of cell-based therapies in blood cancer, describing them according to the cell source.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
O - Projekt operacniho programu
Ostatní
Rok uplatnění
2020
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
CANCERS
ISSN
2072-6694
e-ISSN
2072-6694
Svazek periodika
12
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
23
Strana od-do
—
Kód UT WoS článku
000539246000274
EID výsledku v databázi Scopus
—